100
Trials as lead sponsor
Most active programmes
The drugs appearing most often across Grifols's recently active trials. Comparator arms are excluded.
- Standard Medical Treatment6 trials
- Alpha-1 MP5 trials
- Trimodulin3 trials
- IGSC 20%3 trials
- Fibrin Sealant Grifols3 trials
- GAMUNEX-C3 trials
Upcoming readouts
Next primary completion dates among Grifols's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.
- Sept 2027SWIFT-SC: A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly…Phase 3
- Dec 2027XPERT: A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants …Phase 3
- Jul 2028ESsCAPE: Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (…Phase 3
- Aug 2028SIGMA: A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants W…Phase 3
Top therapeutic areas
Conditions studied most often across Grifols's recently active trials.
- COVID-197 trials
- Primary Immunodeficiency6 trials
- Alpha1-Antitrypsin Deficiency3 trials
- Congenital Afibrinogenemia3 trials
- Multiple Myeloma3 trials
- Hepatitis B, Chronic3 trials
Grifols trials
The 50 most significant of Grifols's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.
| Trial | Phase | Stability | Status | Enrollment | Est. readout |
|---|---|---|---|---|---|
| SPARTAEfficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)NCT01983241Alpha-1 MP | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 345 est. | Aug 2026 |
| SWIFT-SCA Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)NCT07555483Alpha-1 15% | Phase 3 | Locked · track to reveal | OngoingRecruiting | 40 est. | 30 Sept 2027 |
| XPERTA Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating PolyradiculoneuropathyNCT07540221Gamunex-C | Phase 3 | Locked · track to reveal | OngoingRecruiting | 40 est. | 31 Dec 2027 |
| ESsCAPEEfficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)NCT05722938Trimodulin | Phase 3 | Locked · track to reveal | OngoingRecruiting | 590 est. | 31 Jul 2028 |
| SIGMAA Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin LymphomaNCT07582432Gamunex-C, 10% Injectable Solution | Phase 3 | Locked · track to reveal | OngoingRecruiting | 49 est. | 31 Aug 2028 |
| SPARTA-OLELong Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin DeficiencyNCT02796937Alpha-1 MP | Phase 3 | Locked · track to reveal | OngoingEnrolling by invitation | 290 est. | Sept 2028 |
| Efficacy of Alphanate FVIII/VWF Concentrate in Type 3 Von Willebrand PatientsNCT00555555Alphanate SD/HT | Phase 4 | Locked · track to reveal | OngoingActive, not recruiting | 15 est. | Dec 2028 |
| Safety, Pharmacokinetics and Efficacy of an ATIII ConcentrateNCT00319228Plasma-derived AT-III concentrate | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 30 est. | Dec 2028 |
| Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).NCT07264517GRF312 5% | Phase 2 | Locked · track to reveal | Completed | 103 est. | 20 May 2026 |
| EXCELLA Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin LymphomaNCT05645107Xembify | Phase 3 | Locked · track to reveal | OngoingRecruiting | 386 est. | May 2026 |
| A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin DeficiencyNCT04722887Alpha-1 15% | Phase 1 | Locked · track to reveal | Completed | 17 est. | 1 Aug 2025 |
| TRICOVIDEfficacy and Safety of Trimodulin (BT588) in Subjects With CAP Including COVID-19 PneumoniaNCT05531149Trimodulin | Phase 3 | Locked · track to reveal | StoppedTerminated | 107 est. | 5 May 2025 |
| APACHEShort-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5%NCT03702920SMT + PE-A 5% | Phase 3 | Locked · track to reveal | StoppedTerminated | 274 est. | 14 Apr 2025 |
| FIB Grifols Congenital Deficiency for On-demand Treatment and Surgical ProphylaxisNCT04636268FIB Grifols | Phase 3 | Locked · track to reveal | StoppedWithdrawn | 0 est. | Mar 2025 |
| Efficacy and Safety of Fanhdi®, a High-purity Von Willebrand Containing FVIII Concentrate, in Pediatric Patients With Von Willebrand DiseaseNCT02472665plasma-derived FVIII/VWF concentrate | Phase 4 | Locked · track to reveal | StoppedWithdrawn | 0 est. | 10 Dec 2024 |
| PRECIOSAEffects of Long-Term Administration of Human Albumin in Participants With Decompensated Cirrhosis and AscitesNCT03451292Albutein 20% | Phase 3 | Locked · track to reveal | Completed | 410 est. | 21 May 2024 |
| PreCyssionPrevention of Maternal-fetal Cytomegalovirus Transmission After Primary Maternal Infection, GW ≤ 14 (PreCyssion)NCT05170269BT097 | Phase 3 | Locked · track to reveal | StoppedTerminated | 48 est. | 19 Nov 2023 |
| AdFIrstAdjusted Fibrinogen Replacement StrategyNCT03444324BT524 | Phase 3 | Locked · track to reveal | Completed | 222 est. | 25 Sept 2023 |
| FORCEStudy of the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% Dual Inactivation and Filtration (DIF) in Participants With Post-polio SyndromeNCT02176863Flebogamma® 5% DIF | Phase 2 | Locked · track to reveal | StoppedTerminated | 191 est. | 24 Nov 2022 |
| A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary ImmunodeficiencyNCT04566692IGSC 20% | Phase 4 | Locked · track to reveal | Completed | 33 est. | 18 Jul 2022 |
| Safety and Efficacy of USB002 for Respiratory Distress Due to COVID-19NCT04778059USB002 | Phase 2 | Locked · track to reveal | StoppedTerminated | 21 est. | 10 May 2022 |
| A Study of Safety and Efficacy of Fibrin Sealant Grifols as an Adjunct to Haemostasis During Surgery in Paediatric ParticipantsNCT03461406Fibrin Sealant Grifols | Phase 3 | Locked · track to reveal | Completed | 186 est. | 15 Apr 2022 |
| A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral ImmunodeficiencyNCT04561115Gamunex-C | Phase 3 | Locked · track to reveal | Completed | 33 est. | 28 Mar 2022 |
| Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)NCT04547140Liquid Alpha1-Proteinase Inhibitor (Human) | Phase 2 | Locked · track to reveal | StoppedTerminated | 57 est. | 13 Dec 2021 |
| COVID-19A Study to Evaluate the Safety and Efficacy of C19-IG 20% in SARS-CoV-2 Infected Asymptomatic Ambulatory OutpatientsNCT04847141C19-IG 20% | Phase 3 | Locked · track to reveal | StoppedTerminated | 465 est. | 10 Nov 2021 |
| Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19)NCT04480424GAMUNEX-C | Phase 2 | Locked · track to reveal | Completed | 100 est. | 25 Aug 2021 |
| ESsCOVIDEfficacy and Safety of Trimodulin in Subjects With Severe COVID-19NCT04576728Trimodulin | Phase 2 | Locked · track to reveal | Completed | 166 est. | 29 Jun 2021 |
| Study to Evaluate the Safety and Efficacy of Prolastin in Hospitalized Subjects With COVID-19NCT04495101Prolastin | Phase 2 | Locked · track to reveal | Completed | 100 est. | 26 Apr 2021 |
| Study to Evaluate the Safety and Efficacy of High Dose IVIG in Hospitalized Participants With Coronavirus Disease (COVID-19)NCT04432324Intravenous Immune Globulin | Phase 2 | Locked · track to reveal | Completed | 100 est. | 3 Mar 2021 |
| Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency (GTI1401-OLE)NCT02870348Alpha-1 MP | Phase 1 | Locked · track to reveal | Completed | 4 est. | 16 Feb 2021 |
| A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19)NCT04547127Convalescent anti-SARS-CoV-2 MBT Plasma | Phase 2 | Locked · track to reveal | Completed | 200 est. | 4 Feb 2021 |
| Alphanate in Immune Tolerance Induction TherapyNCT03095287Alphanate | Phase 2 | Locked · track to reveal | StoppedTerminated | 2 est. | 18 Sept 2020 |
| Study Evaluating IGSC 20% Flexible Dosing in Treatment-Experienced and Treatment-Naive Subjects With Primary ImmunodeficiencyNCT03814798IGSC 20% daily push versus every 2 weeks pump | Phase 3 | Locked · track to reveal | StoppedWithdrawn | 0 est. | Sept 2020 |
| Pharmacokinetic, Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen DeficiencyNCT02065882BT524 (Part I) | Phase 3 | Locked · track to reveal | Completed | 67 est. | 18 May 2020 |
| Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PIDNCT02810444IgG Next Generation (BT595) | Phase 3 | Locked · track to reveal | Completed | 81 est. | 1 Apr 2020 |
| IG0902Pharmacokinetics, Efficacy, and Safety of Human Plasma-Derived Fibrinogen (FIB Grifols) in Participants With Congenital AfibrinogenemiaNCT02281500Human Plasma-Derived Fibrinogen Concentrate | Phase 1 | Locked · track to reveal | Completed | 24 est. | 11 Nov 2019 |
| Efficacy and Safety of Plasma Exchange With Albutein® 5% in Participants With Amyotrophic Lateral SclerosisNCT02872142Albutein 5% | Phase 2 | Locked · track to reveal | Completed | 12 est. | 15 Aug 2019 |
| Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary ImmunodeficiencyNCT02806986IGSC 20% | Phase 3 | Locked · track to reveal | Completed | 61 est. | 15 May 2019 |
| Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia GravisNCT02473965IGIV-C | Phase 2 | Locked · track to reveal | Completed | 60 est. | Feb 2019 |
| This Clinical Study is to Test Efficacy and Safety of BT595 in Chronic Primary Immune Thrombocytopenia (ITP)NCT02859909BT595 | Phase 3 | Locked · track to reveal | Completed | 34 est. | Dec 2018 |
| Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia ANCT00323856Alphanate SD/HT | Phase 4 | Locked · track to reveal | Completed | 51 est. | 11 Dec 2018 |
| Study of the Safety of USB005 in Healthy VolunteersNCT03615196USB005 (aclerastide) Ophthalmic Solution | Phase 1 | Locked · track to reveal | Completed | 32 est. | 8 Nov 2018 |
| BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple MyelomaNCT01638936BT062 , intravenous administration | Phase 1 | Locked · track to reveal | Completed | 64 est. | 30 Oct 2018 |
| GamaSTANAnti-Hepatitis A Virus, Pharmacokinetics, and Safety of Immune Globulin (Human)NCT03351933Immune Globulin (Human) | Phase 4 | Locked · track to reveal | Completed | 28 est. | 27 Apr 2018 |
| A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis ExacerbationsNCT02413580IGIV-C | Phase 3 | Locked · track to reveal | Completed | 49 est. | Apr 2018 |
| AMBARA Study to Evaluate Albumin and Immunoglobulin in Alzheimer's DiseaseNCT01561053Albumin 5% | Phase 2 | Locked · track to reveal | Completed | 347 est. | 6 Mar 2018 |
| Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiopulmonary BypassNCT02037555AT-III (Human) | Phase 2 | Locked · track to reveal | Completed | 425 est. | 25 Jan 2018 |
| A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia GravisNCT02473952IGIV-C | Phase 2 | Locked · track to reveal | Completed | 62 est. | Jan 2018 |
| BT063 in SLEProof-of-Concept Study With BT063 in Subjects With Systemic Lupus ErythematosusNCT02554019BT063 | Phase 2 | Locked · track to reveal | Completed | 36 est. | 25 Oct 2017 |
| Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary ImmunodeficiencyNCT02604810IGIV-C 10% | Phase 3 | Locked · track to reveal | Completed | 53 est. | Sept 2017 |